#typhoidtackle

A Brief Look at Typhoid Fever

Typhoid fever is a life-threatening illness caused by the bacterium Salmonella Typhi. Those infected experience a sustained high fever as well as weakness, stomach pains, headache, nausea and loss of appetite. If left untreated, the infection can spread and lead to serious complications affecting almost every organ system. According to estimates by the WHO, typhoid causes over 11 million infections and 128,000 deaths globally each year, with children and young adults disproportionately affected. Countries in Southeast Asia, Africa and Latin America have the highest incidence rates. However, outbreaks can occasionally occur even in developed nations experiencing poor sanitation conditions.

How the Oral Vaccine Works

The traditional typhoid vaccines used parenteral administration via injection to provide protection. However, in recent decades researchers developed an effective oral vaccine using a weakened live strain of S. Typhi known as Ty21a. When administered in an enteric-coated capsule, the bacteria colonize the intestine and induce both mucosal and serum antibodies that can prevent infection. Three doses are typically required over a period of days to achieve full immunization. The oral nature allows for easier distribution and administration compared to injection, especially in crowded clinical settings and areas with limited medical infrastructure. It provides protection that lasts for 3 to 5 years in most individuals.

Efficacy Demonstrated in Clinical Trials

Large phase III trials conducted in the late 1980s across Asia,Latin America and the Middle East demonstrated the oral vaccine's efficacy. When provided to thousands of children and adults in typhoid-endemic locations, it was found to reduce the risk of typhoid fever by 63-97% compared to placebo, depending on the region and population studied. Protection emerged 1-2 weeks after the 3 dose course and persisted for years. Follow up studies also highlighted that a single dose could provide temporary protection of around 30-60% until the full schedule is completed. With widespread programmatic use, the vaccine has helped control typhoid outbreaks and reduce disease incidence in high-risk communities.

Safety Profile Established Over Decades of Use

The Ty21a oral typhoid vaccine was granted marketing authorization by the WHO in 1989 after meeting stringent requirements for quality, safety and effectiveness. In the three decades since, it has been administered to tens of millions of individuals globally as part of national vaccination programs and campaigns coordinated by international health agencies. Continued monitoring of safety data from post-marketing experience has reaffirmed the vaccine's excellent tolerability profile. Common self-limiting side effects like mild abdominal pain or discomfort are reported in less than 5% of recipients. Serious adverse reactions are extremely rare. The attenuation process ensures the live bacteria do not persist or multiply extensively in the body. WHO recommendations emphasize the vaccine can be safely used from ages 2 years onwards.

Expanding Accessibility in Disease-Endemic Regions

With its thermostability at room temperature and ease of oral delivery, the unique attributes of the Ty21a vaccine make it well-suited for expanding protection in low-resource regions disproportionately affected by typhoid. Over the last few years, pneumococcal and rotavirus vaccine introductions through large-scale public health programs have demonstrated the feasibility and impact of reaching even remote communities in Southeast Asia and sub-Saharan Africa cost-effectively. Leveraging these immunization platforms could accelerate typhoid control through routine childhood vaccination schemes. International donors have also helped fund mass vaccination campaigns in parts of Pakistan, Bangladesh and Indonesia experiencing ongoing outbreaks. Collective action is still needed to facilitate widespread and equitable adoption so the benefits of this proven intervention can be fully realized.

Concluding Remarks